Lupin unveils generic equivalent of Revatio for Oral Suspension in US
The medication is used to treat erectile dysfunction and pulmonary arterial hypertension.
Mumbai: Global pharma major, Lupin Limited, has announced the launch of Sildenafil for Oral Suspension, 10 mg/mL, having received approval from the United States Food and Drug Administration (USFDA).
The medication is used to treat erectile dysfunction and pulmonary arterial hypertension.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle-East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health areas.
Read also: Lupin bags USFDA nod for Diclofenac Sodium Topical Solution to treat arthritic knee pain
